Alnylam Pharmaceuticals Inc

詳細情報 Alnylam Pharmaceuticals Inc 企業名

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Alnylam Pharmaceuticals Incの企業情報



企業コードALNY

会社名Alnylam Pharmaceuticals Inc

上場日May 28, 2004

最高経営責任者「CEO」Dr. Yvonne L. Greenstreet, M.D.

従業員数2230

証券種類Ordinary Share

決算期末May 28

本社所在地675 W Kendall St

都市CAMBRIDGE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02142-1168

電話番号16175518200

ウェブサイトhttps://www.alnylam.com/

企業コードALNY

上場日May 28, 2004

最高経営責任者「CEO」Dr. Yvonne L. Greenstreet, M.D.

Alnylam Pharmaceuticals Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

事業別USD

会社名

収益

比率

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

他の

50.81M

6.57%

地域別USD

会社名

収益

比率

United States

454.57M

58.75%

Europe

157.01M

20.29%

Net revenues from collaborations

61.50M

7.95%

Rest of World

60.63M

7.84%

Royalty revenue

39.98M

5.17%

事業別

地域別

事業別USD

会社名

収益

比率

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

他の

50.81M

6.57%

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

他の

55.28%

株主統計

比率

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

他の

55.28%

種類

株主統計

比率

Investment Advisor

68.97%

Investment Advisor/Hedge Fund

21.97%

Hedge Fund

3.70%

Research Firm

1.84%

Sovereign Wealth Fund

1.63%

Bank and Trust

1.27%

Pension Fund

1.27%

Corporation

1.05%

Individual Investor

0.42%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

1364

130.85M

99.04%

-1.89M

2025Q2

1300

131.78M

100.54%

-3.28M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Capital World Investors

16.81M

12.82%

+55.38K

+0.33%

Jun 30, 2025

Fidelity Management & Research Company LLC

15.05M

11.48%

+427.38K

+2.92%

Jun 30, 2025

The Vanguard Group, Inc.

13.24M

10.1%

+238.24K

+1.83%

Jun 30, 2025

Capital Research Global Investors

7.19M

5.49%

+36.93K

+0.52%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.53M

4.98%

-199.00K

-2.96%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

4.28M

3.27%

-136.87K

-3.10%

Jun 30, 2025

JP Morgan Asset Management

1.79M

1.37%

-87.08K

-4.64%

Jun 30, 2025

Dodge & Cox

3.20M

2.44%

-154.67K

-4.61%

Jun 30, 2025

State Street Investment Management (US)

3.17M

2.42%

-193.48K

-5.75%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.05M

2.32%

-359.26K

-10.55%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 Alnylam Pharmaceuticals Inc 企業名

Alnylam Pharmaceuticals Incの企業情報

Alnylam Pharmaceuticals Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割